Indivior weighs secondary US listing as sales soar

UK-based Indivior considers a secondary US listing as the opioid addiction treatment maker’s sales surge Indivior has confirmed it is exploring a secondary listing in the US Shares in the FTSE 250-listed company surged nearly 10% in early trading By Jane Denton